Volume 151, Issue 2, Pages 234-237 (August 2016) Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence David W. Dawson Gastroenterology Volume 151, Issue 2, Pages 234-237 (August 2016) DOI: 10.1053/j.gastro.2016.06.032 Copyright © 2016 AGA Institute Terms and Conditions
Figure 1 Single nodule tumors (A) after R0 surgical resection received adjuvant gemcitabine (C) or vehicle treatment (B). The gemcitabine treated tumors showed lower numbers of myeloid-derived suppressor cells (MDSCs) and increase numbers of natural killer (NK) cells. These findings explain in part the lower local recurrence seen with gemcitabine in clinical trials. PDA, pancreatic ductal adenocarcinoma. Gastroenterology 2016 151, 234-237DOI: (10.1053/j.gastro.2016.06.032) Copyright © 2016 AGA Institute Terms and Conditions